A recent study published in the Journal of Translational Medicine, presents important research findings for the 10-15% of GIST patients who lack mutations in KIT, PDGFRA, SDHX or RAS pathway indicators, the primary oncogenic [...]
In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]
Left to Right: Martin Wettstein, Dr. Michael Montemurro, Helga Meier Schnorf, Prof. Abbas Agaimy, Prof. Richard Herrmann GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor (GIST), has awarded [...]
Executive Director Norman Scherzer traveled to Lisbon, Portugal in November to attend the 21st annual meeting of the Connective Tissue Oncology Society (CTOS). CTOS is an annual conference which has grown since its inception [...]
In 2015, we continued to commit funding for our research team in spite of a challenging fundraising landscape. Our research team held a two-day meeting at the Cleveland Clinic, outlining two key projects: A [...]
The Life Raft Group is pleased to announce the release of the tenth issue of The GIST Cancer Journal, the official journal of the Life Raft Group. The journal is intended to serve as [...]
Loxo Oncology announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]
On July 29, 2016 I traveled to Howard University in Washington, DC to be a participant in Vice President Joe Biden’s Cancer Moonshot Summit. This invitation-only event was designed to bring together individuals and [...]
Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]
